Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to $2.7 million.

  • Avadel Pharmaceuticals' Depreciation & Amortization (CF) rose 191.54% to $586,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.5 million, marking a year-over-year increase of 83.19%. This contributed to the annual value of $2.7 million for FY2024, which is 51.81% up from last year.
  • As of FY2024, Avadel Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.7 million, which was up 51.81% from $1.8 million recorded in FY2023.
  • Avadel Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $2.7 million for FY2024, and its period low was $815,000 during FY2021.
  • For the 3-year period, Avadel Pharmaceuticals' Depreciation & Amortization (CF) averaged around $2.0 million, with its median value being $1.8 million (2023).
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Depreciation & Amortization (CF) plummeted by 51.78% in 2021, and later soared by 83.19% in 2022.
  • MRY analysis of 5 years shows Avadel Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.7 million in 2020, then tumbled by 51.78% to $815,000 in 2021, then surged by 83.19% to $1.5 million in 2022, then grew by 18.29% to $1.8 million in 2023, then soared by 51.81% to $2.7 million in 2024.
  • Its Depreciation & Amortization (CF) stands at $2.7 million for FY2024, versus $1.8 million for FY2023 and $1.5 million for FY2022.